Physiomics Plc logo

Physiomics Plc(LSE) PYC

Market Cap£2.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-100%
5 Year-91%
1 Year+24%
1 Month+2%
£0.01
+6.00%
+0.00Today
Physiomics Plc last closing stock price
MetricPriceDate
Last closeGBX 0.532026-10-01
Physiomics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%GBX 0.532026-09-24
1 month+1.94%GBX 0.522026-09-01
3 month+10.53%GBX 0.482026-07-03
Year to date+84.21%GBX 0.292025-12-31
1 year+23.53%GBX 0.432025-10-01
3 year-71.62%GBX 1.852023-10-02
5 year-91.46%GBX 6.152021-10-01
Since inception-99.77%GBX 2.312004-12-20

Physiomics Plc Financials at a Glance

Market Cap

£2.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£1.47M

Net Income (TTM)

-£1.12M

EPS (TTM)

-£0.00

P/E Ratio

-3.28

Dividend

£0.00

Beta (Volatility)

-0.13 (Low)

Price

£0.01

Volume

150,191

Open

£0.01

Previous Close

£0.01

Daily Range

£0.01 - £0.01

52-Week Range

£0.00 - £0.01

Estimated Earnings Date

Sep 30, 2026

PYC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Physiomics Plc

Physiomics Plc, founded in 2001 and headquartered in Oxford, UK, specializes in providing consulting services to pharmaceutical companies. The firm focuses on quantitative pharmacology and computational biology, particularly in oncology research, utilizing its proprietary Virtual Tumour predictive software.

Products and Services
  • Consulting services in quantitative pharmacology
  • Computational biology solutions for oncology
  • Proprietary Virtual Tumour predictive software
Growth Outlook
  • Recent quarterly revenue increased to £498,000, showing growth potential
  • Strong cash position with £257,000 in cash and equivalents
  • Focus on personalized medicine aligns with industry trends
Financial Highlights
  • Trailing twelve months (TTM) revenue of £1.5 million
  • Current ratio of 3.30 indicates strong liquidity
  • Net income for the latest quarter was -£301,000, reflecting ongoing investment
Physiomics Plc operates in the biotechnology sector, providing essential services that support drug development processes. The company's focus on oncology and personalized medicine positions it well within a growing market. Recent financial data indicates a commitment to growth, despite current net losses, as the firm continues to invest in its capabilities and technology. The strong liquidity ratio suggests that Physiomics is well-equipped to navigate its operational challenges while pursuing future opportunities.
AI Generated • Sep 18, 2026

Industry

Life Sciences Tools and Services

CEO

Peter Sargent, PhD

Headquarters

Oxford, OXF OX14 4RY, GB

PYC Financials

Key Financial Metrics (TTM)

Gross Margin

-56.99%

Operating Margin

-56.75%

Net Income Margin

-50.92%

Return on Equity

-89.43%

Return on Capital

-66.14%

Return on Assets

-86.96%

Earnings Yield

-30.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£2.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

453.21M

Volume

150.19K

Avg. Volume

3.56M

Financials (TTM)

Gross Profit

-£1.23M

Operating Income

-£1.25M

EBITDA

-£1.23M

Operating Cash Flow

-£944.28K

Capital Expenditure

-£22.25K

Free Cash Flow

-£966.52K

Cash & ST Invst.

£257.00K

Total Debt

£0.00

Physiomics Plc Performance Analysis

Physiomics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30GBP 830,266N/A
20232023-06-30GBP 597,354-28.1%
20242024-06-30GBP 543,250-9.1%
20252025-06-30GBP 784,00544.3%
Physiomics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-50.6%
Q22024-12-3174.5%
Q42025-06-3038.3%
Q22025-12-319.4%
Physiomics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30GBP -0.00N/A
20232023-06-30GBP -0.0088.5%
20242024-06-30GBP -0.00-8.2%
20252025-06-30GBP -0.00-62.2%
Physiomics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-100.0%
Q22024-12-31-3900.0%
Q42025-06-3099.4%
Q22025-12-31-42.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£498.00K

+30.4%

Gross Profit

-£357.00K

-51.3%

Gross Margin

-71.69%

N/A

Market Cap

£2.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£237.93K

N/A

Employees

10

N/A

Net Income

-£301.00K

-46.1%

EBITDA

-£352.00K

-51.7%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£257.00K

-36.2%

Total Debt

£0.00

N/A

Accounts Receivable

£288.00K

-24.2%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-86.96%

N/A

Return on Invested Capital

-1.38%

N/A

Free Cash Flow

-£204.00K

+42.2%

Operating Cash Flow

-£202.00K

+42.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VAL.LValiRx plc
£0.00+11.11%
POLX.LPolarean Imaging plc
£0.00-20.00%
TCF.LTheracryf Plc
£0.00+2.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$31.76-3.99%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$153.69+3.94%
NKENike
$35.15-0.71%
TQQQProShares Trust - ProShares UltraPro Qqq
$78.73+0.90%

Questions About PYC

What is the current price of Physiomics Plc?

Physiomics Plc is trading at £0.01 per share.

What is the 52-week range for Physiomics Plc?

Over the past 52 weeks, Physiomics Plc has traded between £0.00 and £0.01.

How much debt does Physiomics Plc have?

As of the most recent reporting period, Physiomics Plc reported total debt of £0.00.

How much cash does Physiomics Plc have on hand?

Physiomics Plc reported £461.24K in cash and cash equivalents in its most recent financial results.

What is Physiomics Plc’s dividend yield?

Physiomics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.